Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

News 8 is once again honoring Black history by looking at health care and the racial disparities many report facing.

USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...

Discover Agios Pharmaceuticals' Q4 2024 earnings highlights, growth plans for Pyrukynd in thalassemia & sickle cell, and insights on safety, clinical ...

Agios Pharmaceuticals (AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to less than18 years with PK ...

Over 10000 people in Rajasthan’s tribal districts are affected by Sickle Cell Disease with nearly 3000 testing positive Learn ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Statistically significant means there is a very high likelihood the drug impacted its target. But if data are not clinically ...

SSM Health Cardinal Glennon Children's Hospital partners with Eye See Me African Bookstore to provide books promoting ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

Medical and Health Department of the state confirms over 10,000 patients affected with the dangerous sickle cell disease ...

Understanding Sickle Cell Anemia and the Need for Early DiagnosisSickle cell anemia is a genetic blood disorder caused by a ...